241 related articles for article (PubMed ID: 33813427)
1. Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Ishizaki T; Mazaki J; Enomoto M; Shigoka M; Kasahara K; Matsudo T; Kawakita H; Nagakawa Y; Katsumata K; Tsuchida A
Anticancer Res; 2021 Apr; 41(4):2157-2163. PubMed ID: 33813427
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
[TBL] [Abstract][Full Text] [Related]
4. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
Cecchini M; Kortmansky JS; Cui C; Wei W; Thumar JR; Uboha NV; Hafez N; Lacy J; Fischbach NA; Sabbath KD; Gomez CM; Sporn JR; Stein S; Hochster HS
Cancer; 2021 May; 127(9):1417-1424. PubMed ID: 33351187
[TBL] [Abstract][Full Text] [Related]
6. Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment.
Fujimoto Y; Oki E; Qiu S; Nakanishi R; Makiyama A; Miyamoto Y; Kotaka M; Shimokawa M; Ando K; Kimura Y; Kitao H; Maehara Y; Mori M
Cancer Sci; 2021 Jun; 112(6):2436-2441. PubMed ID: 33780084
[TBL] [Abstract][Full Text] [Related]
7. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
11. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
[TBL] [Abstract][Full Text] [Related]
15. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
[TBL] [Abstract][Full Text] [Related]
16. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y; Yamada T; Kamiyama H; Kosugi C; Ishibashi K; Yoshida H; Ishida H; Yamaguchi S; Kuramochi H; Fukazawa A; Sonoda H; Yoshimatsu K; Matsuda A; Hasegawa S; Sakamoto K; Otsuka T; Koda K;
Int J Clin Oncol; 2021 Jan; 26(1):111-117. PubMed ID: 33083913
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
18. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Nakashima M; Takeuchi M; Kawakami K
Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
